Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first ...

Low-energy DPL therapy significantly improves outcomes among patients with ETR when compared with high-energy DPL therapy.

Investigators examined the effect of postpartum status on the 21-gene Oncotype DX Recurrence Score in women with hormone ...

This multicenter study identifies key clinical and sociodemographic factors associated with fear of cancer recurrence in breast cancer survivors.

Postpartum breast cancer (PPBC) diagnosed within the first year postpartum has a significantly elevated 21-gene Oncotype DX ...

A recent study indicates that breast cancer detected after childbirth could be more aggressive as pregnancy and lactation ...

A new artificial intelligence tool may soon change how doctors understand breast cancer risk, offering faster answers and ...

Steve Borthwick, the England head coach, says that playmaker Marcus Smith has proven that he is a viable option as a ...

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be ...

Prosigna testing identified roughly two-thirds of clinically high-risk patients who could omit adjuvant chemotherapy without meaningful detriment in 5-year invasive breast cancer–free survival.

Chemotherapy decisions for young women with HR+ breast cancer and low recurrence scores reveal testing disparities that health systems must address. AJMC: Your analysis focused on chemotherapy use ...

Sabrina M.’s life was turned upside down in 2011 when she noticed an unusual indentation in one of her breasts. Within weeks of the discovery, the then 40-year-old emergency room nurse and mother of ...